Nexalin Technology, Inc. – NASDAQ:NXL
Nexalin Technology stock price today
Nexalin Technology stock price monthly change
Nexalin Technology stock price quarterly change
Nexalin Technology stock price yearly change
Nexalin Technology key metrics
Market Cap | 32.47M |
Enterprise value | 4.55M |
P/E | -3.22 |
EV/Sales | 2.21 |
EV/EBITDA | -1.87 |
Price/Sales | 2.26 |
Price/Book | 0.85 |
PEG ratio | -0.05 |
EPS | -0.66 |
Revenue | 158.86K |
EBITDA | -5.94M |
Income | -4.94M |
Revenue Q/Q | 157.43% |
Revenue Y/Y | -84.55% |
Profit margin | -122.9% |
Oper. margin | -128.86% |
Gross margin | 74.15% |
EBIT margin | -128.86% |
EBITDA margin | -3740.81% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeNexalin Technology stock price history
Nexalin Technology stock forecast
Nexalin Technology financial statements
| Jun 2023 | 35.54K | -822.43K | -2314.12% |
|---|---|---|---|
| Sep 2023 | 24.11K | -2.29M | -9526.77% |
| Dec 2023 | 20.53K | -780.66K | -3801.47% |
| Mar 2024 | 78.67K | -1.04M | -1323.43% |
| 2025 | 200.34M | 0 |
|---|
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 5175621 | 1.18M | 22.85% |
|---|---|---|---|
| Sep 2023 | 4433767 | 1.19M | 27% |
| Dec 2023 | 3631916 | 425.28K | 11.71% |
| Mar 2024 | 2834210 | 507.22K | 17.9% |
| Jun 2023 | -815.61K | 872.37K | 0 |
|---|---|---|---|
| Sep 2023 | -701.09K | 830.76K | 0 |
| Dec 2023 | -1.00M | 1.22M | 0 |
| Mar 2024 | -763.28K | 729.31K | 0 |
Nexalin Technology alternative data
| Aug 2023 | 6 |
|---|---|
| Sep 2023 | 6 |
| Oct 2023 | 6 |
| Nov 2023 | 6 |
| Dec 2023 | 6 |
| Jan 2024 | 6 |
| Feb 2024 | 6 |
| Mar 2024 | 6 |
| Apr 2024 | 6 |
| May 2024 | 6 |
| Jun 2024 | 6 |
| Jul 2024 | 6 |
Nexalin Technology other data
| Period | Buy | Sel |
|---|---|---|
| Jun 2024 | 4619 | 0 |
-
What's the price of Nexalin Technology stock today?
One share of Nexalin Technology stock can currently be purchased for approximately $0.77.
-
When is Nexalin Technology's next earnings date?
Unfortunately, Nexalin Technology's (NXL) next earnings date is currently unknown.
-
Does Nexalin Technology pay dividends?
No, Nexalin Technology does not pay dividends.
-
How much money does Nexalin Technology make?
Nexalin Technology has a market capitalization of 32.47M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 91.62% to 110.75K US dollars.
-
What is Nexalin Technology's stock symbol?
Nexalin Technology, Inc. is traded on the NASDAQ under the ticker symbol "NXL".
-
What is Nexalin Technology's primary industry?
Company operates in the Healthcare sector and Medical - Devices industry.
-
How do i buy shares of Nexalin Technology?
Shares of Nexalin Technology can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does Nexalin Technology have?
As Jul 2024, Nexalin Technology employs 6 workers.
-
When Nexalin Technology went public?
Nexalin Technology, Inc. is publicly traded company for more then 3 years since IPO on 16 Sep 2022.
-
What is Nexalin Technology's official website?
The official website for Nexalin Technology is nexalin.com.
-
Where are Nexalin Technology's headquarters?
Nexalin Technology is headquartered at 1776 Yorktown, Houston, TX.
-
How can i contact Nexalin Technology?
Nexalin Technology's mailing address is 1776 Yorktown, Houston, TX and company can be reached via phone at +7 136601100.
Nexalin Technology company profile:
Nexalin Technology, Inc.
nexalin.comNASDAQ
6
Medical - Devices
Healthcare
Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. It licenses and markets Nexalin Device, a non-invasive and drug-free therapy for the treatment of anxiety and insomnia. The company's Nexalin device emits a patented frequency-based waveform, which stimulates a positive response from the mid-brain structures associated with various mental health disorders. It also engages in the development of Generation 2, a medical device that is in clinical trials for the treatment of substance abuse issues related to opiates, chronic pain, Alzheimer's disease, and dementia. The company was incorporated in 2021 and is headquartered in Houston, Texas.
Houston, TX 77056
CIK: 0001527352
ISIN: US65345B2016
CUSIP: 65345B201
